Allentis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.95 M
as on 16-11-2024
- Paid Up Capital ₹ 0.95 M
as on 16-11-2024
- Company Age 22 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.50 M
as on 16-11-2024
- Satisfied Charges ₹ 1.50 M
as on 16-11-2024
- Revenue -0.90%
(FY 2023)
- Profit -38.25%
(FY 2023)
- Ebitda -11.52%
(FY 2023)
- Net Worth 9.58%
(FY 2023)
- Total Assets -0.75%
(FY 2023)
About Allentis Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.95 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹6.50 M. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Mathur, Manoj Gurnani, and Dilip Nathani serve as directors at the Company.
- CIN/LLPIN
U24232MP2002PTC015334
- Company No.
015334
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Oct 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Gwalior, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Allentis Pharmaceuticals Private Limited offer?
Allentis Pharmaceuticals Private Limited offers a wide range of products and services, including Health Conditions, Liver Care, Stomach Care.
Who are the key members and board of directors at Allentis Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Nathani  | Director | 16-Oct-2002 | Current |
| Sanjay Mathur | Director | 16-Oct-2002 | Current |
| Manoj Gurnani | Director | 26-Feb-2003 | Current |
Financial Performance of Allentis Pharmaceuticals.
Allentis Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.9% decrease. The company also saw a substantial fall in profitability, with a 38.25% decrease in profit. The company's net worth moved up by a moderate rise of 9.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Allentis Pharmaceuticals?
In 2023, Allentis Pharmaceuticals had a public holding of 34.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Mar 2006 | ₹6.50 M | Open |
Union Bank Of India Creation Date: 09 Jan 2014 | ₹1.00 M | Satisfied |
Union Bank Of India Creation Date: 28 Dec 2006 | ₹0.50 M | Satisfied |
How Many Employees Work at Allentis Pharmaceuticals?
Allentis Pharmaceuticals has a workforce of 32 employees as of May 14, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Allentis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Allentis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
